Tesamorelin – Kodiac biolabs

Plain-language summaryIntrigue 70 / 100

Tesamorelin, sold as Egrifta, is a stabilized GHRH analog FDA-approved for HIV-associated visceral fat accumulation. It produces growth hormone release while preserving the natural pulsatile pattern. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished, active research

57/100

FDA-approved GHRH analog with proven visceral fat reduction and an emerging cognitive research angle worth watching

Look, tesamorelin occupies a genuinely interesting position in the GHRH analog space, and that position is mostly defined by what it has that its competitors dont: a real FDA approval backed by actual phase 3 data. Egrifta got its 2010 nod for HIV-associated lipodystrophy, and that approval is anchored in legitimate multicenter RCTs, not the kind of single-lab preclinical story you see from most peptides in this category. For visceral adipose tissue reduction in patients on antiretroviral therapy, it works, and we have the data to say so with confidence.

The structural story is worth understanding. Native GHRH has a plasma half-life in the 7-10 minute range; sermorelin gets you to roughly 11-12 minutes. Tesamorelin’s trans-3-hexenoic acid conjugation at the N-terminus pushes that to around 26 minutes, and more importantly, it preserves the natural pulsatility of GH release. Thats not a trivial distinction. Exogenous GH replacement suppresses endogenous axis function; tesamorelin stimulates it. Mechanistically that’s the cleaner approach, and researchers interested in GH axis physiology have a real reason to reach for it as a probe compound rather than just injecting GH directly. The downstream IGF-1 signal is physiological, not pharmacological, which matters if you’re trying to isolate axis-specific effects.

Where the score gets complicated is novelty. GHRH analogs are a mature class. CJC-1295 with DAC has a dramatically longer half-life if you’re chasing PK. Sermorelin is cheap and accessible. The tesamorelin story really rests on two things: the regulatory anchor, which you can’t dismiss, and an emerging cognitive research thread that we think is the most interesting active science around this compound right now. Multiple investigator groups have looked at tesamorelin in the context of HIV-associated neurocognitive disorder, with a modest but real signal appearing across several small trials. Whether the effect is GH-mediated, IGF-1-mediated, or something more indirect through neuroinflammatory or metabolic pathways is still being worked out, and that ambiguity is actually what makes it worth watching for any program focused on the neuroendocrine-cognition intersection.

Honestly, for a bench scientist the most defensible use case is as a validated GHRH-axis tool with a real human pharmacokinetic and pharmacodynamic dataset behind it, which is more than most peptides in this class can claim. Sourcing is cleaner than average given approved-drug status and peptide-synthesis availability. We’d put this in the serious-but-not-urgent category: real signal, real data, mechanism that’s established rather than exciting. The cognitive angle could shift the assessment if the next round of trials holds up, but right now it reads as confirmatory work on a known platform rather than something at the frontier.

Novelty: 40
Mechanism promise: 45
In-category differentiation: 62
Evidence quality: 72
Translational signal: 72
Research bench value: 55

Rationale Tesamorelin’s trans-3-hexenoic acid modification and its FDA approval in HIV lipodystrophy give it unusually strong evidence and translational scores for a peptide, but the mechanism is single-receptor agonism in a mature class and novelty is correspondingly modest. The HIV-associated neurocognitive disorder research thread is the most scientifically interesting active direction and keeps it from scoring lower.

Stabilized GHRH analog

A trans-3-hexenoic acid stabilized GHRH analog FDA-approved as Egrifta for HIV-associated lipodystrophy.

Abstract

Tesamorelin (Egrifta; CAS 901758-09-6; molecular weight 5135.79) is a stabilized analog of human GHRH developed by Theratechnologies (Canada) and approved by the FDA in 2010 for HIV-associated lipodystrophy. The structural modification is the addition of a trans-3-hexenoic acid group at the N-terminus, which substantially extends plasma half-life relative to native GHRH or sermorelin. The compound stimulates physiological GH release with restored visceral adipose tissue reduction in HIV patients on antiretroviral therapy. Pharmacokinetics: plasma half-life approximately 26 minutes (versus 11 to 12 minutes for sermorelin); subcutaneous administration. Approved dose is 2 mg subcutaneously once daily.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-080Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.